Insider · CIK 0001804567
Frank Mottola
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.). First filing Nov 8, 2024, latest Mar 10, 2026.
In brief
Frank Mottola files SEC Form 4 as officer at SUPN (SUPERNUS PHARMACEUTICALS, INC.). Since Nov 8, 2024, Frank Mottola has reported 0 open-market buys worth $0 and 5 open-market sells worth $2.5M, the latest filed on Mar 10, 2026.
A track record needs three past buys with six months of prices behind them; Frank Mottola has 0, so none is measured yet.
The newest scored trade: sold $87k of SUPN on Mar 9, 2026, filed Mar 10, 2026, scored 24 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $1.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | SUPERNUS PHARMACEUTICALS, INC. | $87k 1,623 shares | -8% | +79% from low-5% from high | |
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | $1.0M 20,000 shares | -98% | +70% from low-10% from high | |
| 26Weak | SUPERNUS PHARMACEUTICALS, INC. | $229k 5,000 shares | -24% | +52% from low-3% from high | |
| 45Moderate | SUPERNUS PHARMACEUTICALS, INC. | $623k 14,000 shares | -47% | +48% from low-1% from high | |
| 54Moderate | SUPERNUS PHARMACEUTICALS, INC. | $555k 15,000 shares | -65% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 9, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 1,623 0.00% of outstanding | $87k | Mar 9, 2026 | none |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 20,000 0.03% of outstanding | $986k | Dec 19, 2025 | none |
| Sep 12, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 5,000 0.01% of outstanding | $229k | Sep 12, 2025 | $623k |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 14,000 0.03% of outstanding | $623k | Aug 25, 2025 | none |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 15,000 0.03% of outstanding | $555k | Nov 7, 2024 | none |
| Nov 14, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 1,110 0.00% of outstanding | $31k | Nov 14, 2023 | none |
Transactions
Every row this insider has filed, 38 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,650 | $0.00 | $0 | 20,341 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -797 | $46.57 | $37k | 19,544 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,650 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,650 | $0.00 | $0 | 1,650 | Jul 31, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 21,856 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,793 | $54.73 | $98k | 20,063 | Mar 10, 2026 |
| Mar 9, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -1,623 | $53.65 | $87k | 18,440 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -3,750 | $0.00 | $0 | 0 | Mar 10, 2026 |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +3,750 | $0.00 | $0 | 3,750 | Mar 3, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,875 | $0.00 | $0 | 19,083 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -977 | $50.69 | $50k | 18,106 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,875 | $0.00 | $0 | 1,875 | Feb 26, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,125 | $0.00 | $0 | 16,849 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -603 | $51.35 | $31k | 16,246 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +750 | $0.00 | $0 | 16,996 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -368 | $50.86 | $19k | 16,628 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,250 | $0.00 | $0 | 17,878 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -670 | $50.86 | $34k | 17,208 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,125 | $0.00 | $0 | 3,375 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -750 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,250 | $0.00 | $0 | 2,500 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Feb 20, 2026 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,000 | $39.40 | $197k | 20,496 | Dec 22, 2025 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -5,000 | $50.22 | $251k | 15,496 | Dec 22, 2025 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +15,000 | $25.30 | $380k | 30,496 | Dec 22, 2025 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -15,000 | $50.47 | $757k | 15,496 | Dec 22, 2025 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 0 | Dec 22, 2025 |
| Dec 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 0 | Dec 22, 2025 |
| Sep 12, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +5,000 | $39.40 | $197k | 20,496 | Sep 15, 2025 |
| Sep 12, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -5,000 | $45.87 | $229k | 15,496 | Sep 15, 2025 |
| Sep 12, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 5,000 | Sep 15, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +14,000 | $12.98 | $182k | 29,496 | Aug 27, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -14,000 | $44.51 | $623k | 15,496 | Aug 27, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative | -14,000 | $0.00 | $0 | 0 | Aug 27, 2025 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +15,000 | $9.13 | $137k | 23,200 | Nov 8, 2024 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -15,000 | $36.98 | $555k | 8,200 | Nov 8, 2024 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Nov 8, 2024 |
Questions about Frank Mottola
Answered from the filings on this page, as of the latest one.
Is Frank Mottola buying or selling?
In the last 12 months Frank Mottola reported 0 open-market buys worth $0 and 2 open-market sells worth $1.1M on SEC Form 4; the latest was sold $87k of SUPN on Mar 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Frank Mottola's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Frank Mottola has 0.
Where does Frank Mottola file Form 4?
Frank Mottola has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.) as SVP, Chief Tech. Ops. Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.